SCLC Clinical Trials

48 clinical trials for SCLC across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• A Study of ZL-1310 in Subjects With Small Cell Lung Cancer — RECRUITING · PHASE1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC — RECRUITING · PHASE1
• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer — RECRUITING · PHASE1
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer — RECRUITING · PHASE2
• Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC — RECRUITING · PHASE2
• A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors — RECRUITING · PHASE1
• Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection — RECRUITING
• Cognitive Screening in Lung Cancer Patients — RECRUITING
• Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study — RECRUITING · PHASE2
• Adebrelimab + Apatinib in SCLC Maintenance Therapy — RECRUITING · PHASE2
• Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) — RECRUITING
• Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer — OTHER
• A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors — COMPLETED · PHASE1
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) — NOT_YET_RECRUITING · PHASE3
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. — ACTIVE_NOT_RECRUITING · PHASE1
• GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 — TERMINATED · PHASE1
• PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — ACTIVE_NOT_RECRUITING · NA
• Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Oral MRT-2359 in Selected Cancer Patients — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer — COMPLETED · PHASE1
• Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms — ACTIVE_NOT_RECRUITING · PHASE2
• Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors — COMPLETED · PHASE1
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC — ACTIVE_NOT_RECRUITING · PHASE2
• Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study — NOT_YET_RECRUITING · PHASE2
• A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC — ACTIVE_NOT_RECRUITING · PHASE2
• TAS-116 Plus Palbociclib in Breast and Rb-null Cancer — WITHDRAWN · PHASE1
• Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell — NOT_YET_RECRUITING · PHASE3
• Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases — COMPLETED · NA
• Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer — TERMINATED · PHASE1
• A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer — COMPLETED · PHASE1
• Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer — COMPLETED · NA
• Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab — WITHDRAWN · PHASE1
• Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC — OTHER · PHASE3
• Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] — COMPLETED · PHASE2
• Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer — OTHER · PHASE2
• Pazopanib Maintenance for SCLC — COMPLETED · PHASE2
• A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations — TERMINATED · PHASE2
• Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer — COMPLETED · PHASE2
• Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment — OTHER
• A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection — TERMINATED · PHASE1
• Pazopanib in Relapsed and Refractory Small Cell Lung Cancer — COMPLETED · PHASE2
• BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors — COMPLETED · PHASE1
• Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer — COMPLETED · PHASE2
• A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy — TERMINATED · PHASE1
• Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation — TERMINATED · PHASE3

Refine this search